Who makes STK-001 - Single Ascending Doses?

STK-001 - Single Ascending Doses is developed by Stoke Therapeutics, Inc.

What development phase is STK-001 - Single Ascending Doses in?

STK-001 - Single Ascending Doses is in Phase 1.

Last reviewed 2026-05-13 · How we verify

STK-001 - Single Ascending Doses

Stoke Therapeutics, Inc · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	STK-001 - Single Ascending Doses
Sponsor	Stoke Therapeutics, Inc
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet Syndrome (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

STK-001 - Single Ascending Doses CI brief — competitive landscape report
STK-001 - Single Ascending Doses updates RSS · CI watch RSS
Stoke Therapeutics, Inc portfolio CI